Weight Loss and Obesity Management Market, by Product & Services (Drugs, Supplements, Equipment, and Services), by Age Group (Children, Adults, and Geriatric), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - S

Weight Loss and Obesity Management Market, by Product & Services (Drugs, Supplements, Equipment, and Services), by Age Group (Children, Adults, and Geriatric), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

Obesity refers to body fat and body mass index above 25 (overweight) and 30 (obese), respectively. It is one of the most prevalent disease conditions across the world. It affects individuals in developed, emerging, and undeveloped regions. The weight loss and obesity management services involve the use of certain products such as dietary supplements, medications, surgical interventions, and fitness equipment. According to the World Health Organization, when the Body-Mass-Index is greater than or equal to 25, the person is categorized as overweight; and BMI index above 30 is classified as obese.

Market Dynamics

Increasing incidence of obesity in developed and developing economies of the world is expected to assist growth of the weight loss and obesity management market during the forecast period. For instance, according to the WHO reports published in 2018, around 35.8 million disabilities worldwide are caused due to obesity. Furthermore, increasing research and development, and adoption of strategies such as collaborations and development of novel products by market players to expand their geographical footprint is expected to drive growth of the weight loss and obesity management market.

Key features of the study:

• This report provides in-depth analysis of the global weight loss and obesity management market and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global weight loss and obesity management market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Novo Nordisk A/S, Takeda Pharmaceutical Company Ltd, Eisai Co., Ltd., F. Hoffmann-La Roche Ltd, VIVUS Inc., Herbalife Ltd., Apollo Endosurgery (U.S.), Amer Sports, Brunswick Corporation, Cybex International, Duke Products & Services & Fitness Center, Ethicon Inc., Equinox, Inc., Johnson & Johnson Services, Inc., Kellogg Company, Life Time Fitness Inc., Medtronic, and NutriSystem, Inc.
• Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, technology up gradation, market expansion, and marketing tactics
• The global weight loss and obesity management market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global weight loss and obesity management market

Detailed Segmentation:

• Global Weight Loss and Obesity Management Market, By Product & Services:
• Drugs
• Bupropion-naltrexone (Contrave)
• Liraglutide (Saxenda)
• Lorcaserin (Belviq)
• Orlistat (Xenical)
• Phentermine-topiramate (Qsymia)
• Others
• Supplements
• Equipment
• Fitness Equipment
• Surgical Equipment
• Services
• Consulting Service
• Online Weight Loss Programs
• Others
• Global Weight Loss and Obesity Management Market, By Age Group:
• Children
• Adults
• Geriatrics
• Global Weight Loss and Obesity Management Market, By Region:
• North America
• By Product & Services:
• Drugs
• Bupropion-naltrexone (Contrave)
• Liraglutide (Saxenda)
• Lorcaserin (Belviq)
• Orlistat (Xenical)
• Phentermine-topiramate (Qsymia)
• Others
• Supplements
• Equipment
• Fitness Equipment
• Surgical Equipment
• Services
• Consulting Service
• Online Weight Loss Programs
• Others
• By Age Group:
• Children
• Adults
• Geriatrics
• By Country:
• U.S.
• Canada
• Latin America
• By Product & Services:
• Drugs
• Bupropion-naltrexone (Contrave)
• Liraglutide (Saxenda)
• Lorcaserin (Belviq)
• Orlistat (Xenical)
• Phentermine-topiramate (Qsymia)
• Others
• Supplements
• Equipment
• Fitness Equipment
• Surgical Equipment
• Services
• Consulting Service
• Online Weight Loss Programs
• Others
• By Age Group:
• Children
• Adults
• Geriatrics
• By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Product & Services:
• Drugs
• Bupropion-naltrexone (Contrave)
• Liraglutide (Saxenda)
• Lorcaserin (Belviq)
• Orlistat (Xenical)
• Phentermine-topiramate (Qsymia)
• Others
• Supplements
• Equipment
• Fitness Equipment
• Surgical Equipment
• Services
• Consulting Service
• Online Weight Loss Programs
• Others
• By Age Group:
• Children
• Adults
• Geriatrics
• By Country:
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Product & Services:
• Drugs
• Bupropion-naltrexone (Contrave)
• Liraglutide (Saxenda)
• Lorcaserin (Belviq)
• Orlistat (Xenical)
• Phentermine-topiramate (Qsymia)
• Others
• Supplements
• Equipment
• Fitness Equipment
• Surgical Equipment
• Services
• Consulting Service
• Online Weight Loss Programs
• Others
• By Age Group:
• Children
• Adults
• Geriatrics
• By Country:
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Product & Services:
• Drugs
• Bupropion-naltrexone (Contrave)
• Liraglutide (Saxenda)
• Lorcaserin (Belviq)
• Orlistat (Xenical)
• Phentermine-topiramate (Qsymia)
• Others
• Supplements
• Equipment
• Fitness Equipment
• Surgical Equipment
• Services
• Consulting Service
• Online Weight Loss Programs
• Others
• By Age Group:
• Children
• Adults
• Geriatrics
• By Country:
• GCC
• Israel
• Rest of Middle East
• Africa
• By Product & Services:
• Drugs
• Bupropion-naltrexone (Contrave)
• Liraglutide (Saxenda)
• Lorcaserin (Belviq)
• Orlistat (Xenical)
• Phentermine-topiramate (Qsymia)
• Others
• Supplements
• Equipment
• Fitness Equipment
• Surgical Equipment
• Services
• Consulting Service
• Online Weight Loss Programs
• Others
• By Age Group:
• Children
• Adults
• Geriatrics
• By Country/Region:
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Novo Nordisk A/S *
• Company Overview
• Product Portfolio
• Financial Performance
• Key Highlights
• Market Strategies
• Takeda Pharmaceutical Company Ltd
• Eisai Co., Ltd.
• F. Hoffmann-La Roche Ltd
• VIVUS Inc.
• Herbalife Ltd.
• Apollo Endosurgery (U.S.)
• Amer Sports
• Brunswick Corporation
• Cybex International
• Ethicon, Inc.
• Equinox, Inc.
• Johnson & Johnson Services, Inc.
• Kellogg Company
• Life Time Fitness Inc.
• Medtronic
• NutriSystem, Inc.

“*” marked represents similar segmentation in other categories in the respective section.